Morningstar - COSCO SHIPPING Ports Limited (01199) CSPâ€™s 2017 Result In Line; Port Operation Improved in Second Half

Report

Morningstar

Jennifer Song

EUR 101.80 For Business Accounts Only

CSPâ€™s 2017 Result In Line; Port Operation Improved in Second Half

No-moat Cosco Shipping Portsâ€™ full-year 2017 results revealed an improved port operation in the second half, driven by strong throughput volume growth with benefits from global trade recovery and the recently formed Ocean Alliance. The companyâ€™s core profit rose 12% year over year to USD 117 million in the second half, or 18% sequentially, on the back of decent 13% throughput volume growth from a year ago. This is in line with our expectation, and we maintain both our earnings forecasts and our ...

27/03/2018 13 EN

Underlying

COSCO SHIPPING Ports Limited

Cosco Shipping Ports is an investment holding company. Through its subsidiaries, Co. is principally engaged in the businesses of managing and operating terminals, container leasing, management and sale, and their related businesses. Co. is organized into the following operating segments: terminals and related businesses including terminal operations, container handling, transportation and storage; and container leasing, management, sale and related businesses.

See profile

BMG2442N1048 Hong Kong Stock Exchange Bermuda

Provider

Morningstar

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.

Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.

We have operations in 27 countries.

See profile

Analysts

Jennifer Song

Other Reports on these Companies

TheScreener

COSCO SHIPPING PORTS reduced its risk exposure resulting in an upgrade to Slightly Positive

COSCO SHIPPING PORTS (HK), a company active in the Marine Transportation industry, reduced its market risk and raised its general evaluation. The independent financial analyst theScreener awarded an improved star rating to the company, which now shows 3 out of 4 possible stars; its market behaviour has improved and can be considered as moderately risky. theScreener believes that this new assessment merits an overall rating upgrade to Slightly Positive. As of the analysis date February 19, 2021, the closing price was HKD 5.70 and its potential was estimated at HKD 6.78.

Free Trial

February 20, 2021 February 20, 2021 6 EN

SmartInsider

Cosco Shipping Ports Limi: 2 directors bought/maiden bought

Two Directors at Cosco Shipping Ports Limi bought/maiden bought 706,000 shares at between 3.713HKD and 3.740HKD. The significance rating of the trade was 66/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is rest...

Free Trial

April 1, 2020 April 1, 2020 1 EN

Morningstar

Morningstar | CSP's 1Q Results Disappoint; Lowering FVE to HKD 9.30

We lower our fair value estimate for no-moat Cosco Shipping Ports to HKD 9.30 from HKD 9.80 following a disappointing first quarter that missed our expectations. We think the miss is largely attributable to lower-than-expected handling tariffs, due to an unfavorable throughput mix, with lower-valued transshipment volume outpacing overall throughput growth. Weâ€™re reducing our full-year tariff assumption to a 3% decline from the original forecast of a flat tariff. Accordingly, we lower our full-year 2019 net profit forecast by 12% to USD 320 million, which also incorporates the one-off disposa...

EUR 850.00

April 26, 2019 April 26, 2019 3 EN

Business as Usual for No-Moat Lonza; Specialty Ingredients Carve-Out on Track for 2020

Contract manufacturer Lonza reported solid half-year results, with over CHF 2.9 billion in total sales year to date, up about 6.4% from last year and boosted by foreign exchange tailwinds. Core EBITDA margin expanded 30 basis points from last year to about 27.8%, helped slightly by new accounting standards. Management indicated that it continues to expect mid- to high-single-digit sales growth in 2019. We are maintaining our fair value estimate of CHF 210 per share and our no-moat rating. The ph...

EUR 100.00

July 25, 2019 July 25, 2019 13 EN

Joe Gemino

Joe Gemino

Sasol Provides Full-Year Production Update

No-moat Sasol provided an update on its full-year fiscal 2019 production metrics that included relatively stable liquids production. For the full year ended June 30, Sasol produced 1,470 thousand barrels of crude oil and condensate a day compared with 1,469 mboe/d in the year-ago period. However, declines continued with the companyâ€™s natural gas production, down 4% to 130.3 billion cubic feet compared with the period ended June 30, 2018. Sasol also reported flat refined products of 31.4 mmboe/d ...

EUR 100.00

July 25, 2019 July 25, 2019 12 EN

Damien Conover

Damien Conover

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

We don't expect any major changes to our AstraZeneca fair value estimate following second-quarter results that largely fell in line with our expectations and slightly ahead of consensus expectations. Overall, the company is posting leading Big Pharma sales growth with total sales up 18% operationally year over year, led by impressive cancer drug sales growth of 57%. Astra's ability to continue to bring next generation drugs to the market that address unmet medical need (especially in oncology) s...

EUR 100.00

July 25, 2019 July 25, 2019 14 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

CSPâ€™s 2017 Result In Line; Port Operation Improved in Second Half

COSCO SHIPPING PORTS reduced its risk exposure resulting in an upgrade to Slightly Positive

Cosco Shipping Ports Limi: 2 directors bought/maiden bought

Morningstar | CSP's 1Q Results Disappoint; Lowering FVE to HKD 9.30

Business as Usual for No-Moat Lonza; Specialty Ingredients Carve-Out on Track for 2020

Sasol Provides Full-Year Production Update

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe